UVA CENTER FOR DIABETES TECHNOLOGY  
Diabetes
 Closed- Loop Project 6 (DCLP6): Fully 
Automated Closed -Loop Control in Type 1 
Diabetes Using Meal Anticipation   
Protoc
ol Chair  
Sue A. Brown, MD  
Univers
ity of Virginia  
Center for Diabetes Technology  
Versio
n Number: v 2.2 
18-Nov-2021[STUDY_ID_REMOVED]
CLINICAL PROTOCOL     
 
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 2 of 60 
  
KEY ROLES  
 
Protocol Principal Investigator   
Name, degree  Sue Brown, MD  
Institution Name  University of Virginia Center for Diabetes Technology  
  
CLINICAL PROTOCOL     
 
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 3 of 60 
  
PROTOCOL VERSION HISTORY  
Version 
Number  Author(s)  Approver  Effective 
Date  Revision Description  
1.0 Mark DeBoer  Sue Brown  11-Feb-2021  Original Protocol  
1.1 Mary Oliveri   08-Mar -
2021  FDA Review:  
• Removed Fiasp  
• Added monitoring 
description (section 7.4 ) 
• Added fingerstick blood glucose mitigation ( 6.4 and 
7.6) 
• Updated Overall Study Stopping Criteria (section 11.10.2 ) 
• Clarified transition to 
personal equipment at study end (section 6.7 and 7.9 
• Replaced Figure 1 and 
Figure 2 
1.2 Mary Oliveri   21-Mar -
2021  DSMB Review:  
• Mealtime clarifications 
(section  5.3.1. 6.5. 7.7) 
o Minimum/maximum 
carbohydrate  
o Bolus ent ry  
o Carb counting  
• Discharge ketone  values  
clarified  (section Chapter 8 ) 
• Glycemic Treatment 
Guideline added as new 
chapter ( Chapter 8 ) and 
removed as appendix item  
1.3 Mary Oliveri    IRB FB Review : 
CLINICAL PROTOCOL     
 
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 4 of 60 
  
• Remove d all references to 
Medical Monitor; replaced 
with  study PI oversight .  
• ABACUS questionnaire 
removed  from protocol.   
• Deleted DHHS 46.405 
reference removed from 
protocol.  
• Added Statistical and Analytic Plans (section 14.1
) 
and Statistical Hypotheses 
(section 14.2 ).  
1.4 IRB Reviewer   14-May -
2021  IRB FB Reviewer:  
• Removal of edit that was 
not required by the full 
board and could not be 
included in the conditional 
approval.   
1.5 Mary Oliveri   24-May -
2021  Study Team Modifications:  
• Protocol Table Endpoint  
correction :  The primary 
outcome will be time in range 70- 180 mg/dL for the 
period between breakfast and lunch (approximately 
5h). 
• Inclusion criteria edit to 
clarification purposes (section 3.4) 
• Removed Accu -Chek study 
glucometer to remain 
consistent with informed 
consent form that states personal glucometer will be used in trial  (section 2.3).   
• Removed questionnaire 
reference (Chapter 5 ).  
CLINICAL PROTOCOL     
 
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 5 of 60 
  
• Modified COVID policy to 
include CDC and local 
guidelines (section 10.3.1).  
• Modified several references 
to COVID -19 PCR test to FDA 
authorized COVID -19 test.   
• Moved Chapter 9 Medical 
Monitor details to Chapter 
11 (section  6.9 & 7.10) .  
• Deleted Medical Monitor 
chapter (formerly Chapter 
9).  
1.6 Mary Oliveri  Sue Brown  14-Jul-2021 Study Team Modifications:  
• Removed COVID -19 
references in study design 
definition (section 1.3).  
• Added willingness to 
provide a copy of COVID -19 
vaccination record if 
available (section 3.4).  
• Modified COVID -19 policy 
(section 10.3 ). 
1.7 Mary Oliveri  Sue Brown  20-Jul-2021 Study Team Modifications:  
• Corrected definition of CDC  
2.0 Mary Oliveri  Sue Brown, 
Mark DeBoer  10-Sep-2021  Study Team Modifications:  
• Increased enrollment goal 
from 18 participants to 36 
participants ; up to 60 
participants may sign 
consent  (Protocol summary, 
section  1.2, 1.3, 1.6.1, 3.1) 
• Increased from a 3 -night 
overnight stay to a 4 -night 
overnight stay; increased 
hotel admission from about 
76 hours to about 92 hours  
(Protocol Summary, section 
7.1) 
CLINICAL PROTOCOL     
 
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 6 of 60 
  
• Additional admission hours 
reflect increase in 
stabilization period (section 
1.3.4) 
• Edited figure 2 ( Figure 2) 
• Medical monitor and DSMB 
references removed (section 
11.9  
2.1 Mary Oliveri  Sue Brown  11-Nov-
2021  IRB FB Reviewer (prior to 
meeting)  / edited 1 0-Sep-2021 
version : 
• Re-inserted DSMB 
monitoring  (section 11.11) 
• Sample size description 
edited (section 13.4 ) 
2.2 Mary Oliveri  Sue Brown  18-Nov-
2021  IRB FB Review ( prior to 
meeting/ edited 11 -Nov-2021 
version:  
• Deleted that phase 1 
participants may participate 
in phase 2 (section 1.6.1 ) 
  
CLINICAL PROTOCOL     
 
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 7 of 60 
  
SITE PRINCIPAL INVESTIGATOR STATEMENT OF COMPLIANCE  
 
Protocol Title: Diabetes Closed Loop Project 6 (DCLP6): Fully Automated Closed Loop Control in 
Type 1 Diabetes Using Meal Anticipation  
Protocol Version  v2.2 
Protocol Date:  18-Nov-2021  
I have read the protocol specified above.  In my formal capacity as a Site Principal Investigator, 
my duties include ensuring the safety of the study participants enrolled under my supervision.  It 
is understood that all information pertaining to the study will be held strictly confidential and that this confidentiality requirement applies to all study staff at this site.  
This trial will be carried out in accordance with ICH E6 Good Clinical Practice (GCP) and as required 
by the following: United States (US) Code of Federal Regulations (CFR) applicable to clinical 
studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812).  
As the Principal Investigator, I will assure that no deviation from, or changes to the protocol will take place without prior agreement from the sponsor and documented appro val from the 
Institutional Review Board (IRB), or other approved Ethics Committee, except where necessary to eliminate an immediate hazard(s) to the trial participants.  
All key personnel (all individuals responsible for the design and conduct of this trial) have completed Human Participants Protection Training and Good Clinical Practice Training.  Further, I agree to ensure that all staff members involved in the conduct of this study are informed about 
their obligations in meeting the above commitments.  
 
Investigator’s Signature __________________________________ Date: _____ / _____ / _____  
Investigator’s Name: ________________________________  
Site Name:  University of Virginia  
  
CLINICAL PROTOCOL     
 
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 8 of 60 
  
LIST OF ABBREVIATIONS  
ABBREVIATION  DEFINITION  
ADRR  Average Daily Risk Range  
AP Artificial Pancreas  
BG Blood Glucose  
BT/BTLE  Bluetooth, Bluetooth low energy  
CGM Continuous Glucose Monitoring  
CLC Closed -Loop Control  
CiQ Tandem t:slim X2 Insulin Pump with Control -IQ Technology  
CSII Continuous Subcutaneous Insulin Injection  
DKA Diabetic Ketoacidosis  
DSMB  Data Safety Monitoring Board  
FCL Fully Closed Loop  
FCL+  Fully Closed Loop with meal anticipation module  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HbA1c  Hemoglobin A1c  
HBGI  High Blood Glucose Index  
HCL Hybrid Closed Loop  
IDE Investigational Device Exemption  
IOB Insulin -on-Board  
LBGI  Low Blood Glucose Index  
POC Point -of-Care 
QC Quality Control  
rMPC  Regular Model Predictive Control  
UI User Interface  
  
CLINICAL PROTOCOL     
 
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 9 of 60 
  
PROTOCOL SUMMARY  
PARTICIPANT AREA  DESCRIPTION  
Title  Fully Automated Closed -Loop Control  (FCL) in Type 1 Diabetes Using Meal Anticipation  
Investigational Device  UVA Model Predictive Control Artificial Pancreas (RocketAP) with and without prandial 
excursion anticipation  
Objectives  The purpose of this study is to show the safety and feasibility of a fully new fully automated 
AP controller based on meal anticipation  and carbohydrate  kinetics estimation, within the 
UVA AP modular arch itecture.  
Study Design  A randomized cross -over trial  assessing glycemic responses to three different approaches to 
insulin dosing for carbohydrate ingestion all run on an automated insulin delivery  AP system :  
1) FCL: without a meal anticipation module and without announced carbohydrate  
2) FCL+: using a meal anticipation module without announced carbohydrate, and  
3) HCL: without a meal anticipation module with announced carbohydrate  
Number of Sites  One 
Endpoint  The primary outcome will be time in range 70 -180 mg/dL  for the period between breakfast 
and lunch (approximately 5h)  
Population  Key Inclusion Criteria  
• Age 18 and <70 years of age  
• Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one 
year  
• Currently using insulin for at least six months  
• Currently using insulin pump for at least three months  
Sample Size   • Pilot Study: complete up to 3 participant s  
• Main Study: complete up to 36 participants  
Treatment Groups  • Randomized cross over: RocketAP with out meal anticipation module without meal  bolus 
(FCL), RocketAP with meal anticipation module without meal  bolus (FCL+), and RocketAP 
without meal anticipation module with meal  bolus (HCL).  
Participant Duration  Data Collection  Phase of approximately 4 weeks followed by a  hotel/rental house  admission 
as follows:  
• Pilot  Study:  Participants will be admitted to a local hotel or rental house for up to 
approximately 92 hours and will have a dinner with the Rocket AP with  meal anticipation 
and no-carbohydrate announcement.    
• Main Study: Participants will be admitted to a local hotel for approximately 92 hours.  
Protocol Overview/Synopsis  Participants  will be followed for 4 weeks prior to the hotel study.  During this data collection 
phase,  they will wear the study CGM and be instructed to eat breakfast and dinner at 
approximately the same time 4 -5 times per week.  They will then be admitted to the hotel 
for a 4-night study, receiving the three controller sessions in random order: 1) FCL: without a 
meal anticipation module a nd without announced carbohydrate , 2) FCL+: with the meal 
anticipation module and without announced carbohydrate, and 3) HCL: without the meal 
anticipation module and with announced carbohydrate . During the admission, participa nts 
CLINICAL PROTOCOL     
 
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 10 of 60 
  
will receive structured m eals and have blood glucose control followed to compare time in 
range 70 -180 mg/dL between Controller sessions .   
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 11 of 60 
  STUDY VISITS AND PROCEDURES SCHEDULE   
  
Screening  Study 
Equipment 
Training  CGM Run- In 
Phase  Data Collection  Pre-Admission 
Check -In Study 
Admission  Post -
Admission 
Check -In 
Location  Clinic/   
Remote Clinic/   
Remote Home  Home  Phone/  
Email/Text  Hotel /Rental 
House  Phone/  
Email/Text  
Visit  1 2 x x 3 4 5 
Informed Consent  X       
Eligibility Assessment  X       
Medical History  X       
HbA1c  X       
Pregnancy test (if 
applicable)  X X    X  
Physical Exam  X       
Vital Signs (height/weight)  X     X  
Randomization       X  
COVID -19 Testing , non -
vaccinated participants      X X (main study 
only)   
CGM Use   ~14 days if 
needed  X  X  
Survey   X X   X  
Review diabetes 
management and AEs    X   X X 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 12 of 60 
  Table of Contents  1 
Chapter 1  Background ........................................................................................................... 16 2 
1.1 Introduction  ........................................................................................................................ 16 3 
1.2 Study Object ive ................................................................................................................... 17 4 
1.3 Study Design ........................................................................................................................ 17 5 
1.4 Study Device Download  ...................................................................................................... 21 6 
1.5 Study System Issues  ............................................................................................................ 21 7 
1.6 Purpose/Objectives of Clinical Study  .................................................................................. 21 8 
Chapter 2  Study Devices  ....................................................................................................... 22 9 
2.1 Insuli n Pump  ....................................................................................................................... 22 10 
2.2 Continuous Glucose Monitor  .............................................................................................. 22 11 
2.3 Blood Glucose Meter and Strips  ......................................................................................... 22 12 
2.4 Ketone Meter and Strips  ..................................................................................................... 22 13 
2.5 St udy Devices Accountability Procedures  ........................................................................... 22 14 
Chapter 3  Study Screening  .................................................................................................... 23 15 
3.1 Participant Recruitment and Enrollment  ............................................................................ 23 16 
3.2 Informed Consent and Authorization Procedures  .............................................................. 23 17 
3.3 Screening Procedures  ......................................................................................................... 23 18 
3.4 Participant Inclusion Criteria ............................................................................................... 23 19 
3.5 Participant Exclusion Criteria  .............................................................................................. 24 20 
3.6 Eligibility Screening Procedures  .......................................................................................... 25 21 
3.7 Demographic Data Survey  .................................................................................................. 26 22 
Chapter 4  Randomization  ..................................................................................................... 27 23 
4.1 Pilot Study Participants  ....................................................................................................... 27 24 
4.2 Main Study Participants  ...................................................................................................... 27 25 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 13 of 60 
  Chapter 5  Study Equipment Training  ..................................................................................... 28 26 
5.1 CGM Training  ...................................................................................................................... 28 27 
5.2 Activity Tracker  ................................................................................................................... 28 28 
5.3 Study Insulin Pump  ............................................................................................................. 29 29 
Chapter 6  Pilot Study  ............................................................................................................ 30 30 
6.1 Data Col lection Phase  ......................................................................................................... 30 31 
6.2 Qualifications and Role of the Staff  .................................................................................... 30 32 
6.3 Pre -Admission Check -In Visit  .............................................................................................. 30 33 
6.4 Admission Check -In ............................................................................................................. 31 34 
6.5 Study Meals  ......................................................................................................................... 31 35 
6.6 Admission Activities  ............................................................................................................ 32 36 
6.7 Admission Discharge  ........................................................................................................... 32 37 
6.8 Post Admission Check -In Visit  ............................................................................................. 32 38 
Chapter 7  Main Study  ........................................................................................................... 33 39 
7.1 Hotel Admission  .................................................................................................................. 33 40 
7.2 Data Collection Phase (CGM/Meal Entrainment period)  ................................................... 33 41 
7.3 Qualifications and Role of the Staff  .................................................................................... 33 42 
7.4 Pre -Admission Check -In Visit  .............................................................................................. 34 43 
7.5 Admission Check -In ............................................................................................................. 34 44 
7.6 Study Meals ......................................................................................................................... 35 45 
7.7 Admission Activities  ............................................................................................................ 36 46 
7.8 Admission Discharge  ........................................................................................................... 36 47 
7.9 Post Admission Check -In Visit  ............................................................................................. 36 48 
Chapter 8  Glycemic Treatment Guidelines  ............................................................................ 37 49 
Chapter 9  Testing Procedures  ............................................................................................... 38 50 
9.1 Laboratory / Point of Care Testing  ...................................................................................... 38 51 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 14 of 60 
  Chapter 10  Risks Associated with Clinical Trial  ...................................................................... 39 52 
10.1 Potential Risks and Benefits of the Investigational Device  ............................................... 39 53 
10.2 General Considerations ..................................................................................................... 43 54 
10.3 COVID -19 Risk Mitigation Plan and Justification  .............................................................. 43 55 
Chapter 11  Adverse Events, Device Issues, and Stopping Rules  ............................................. 44 56 
11.1 Definitions ......................................................................................................................... 44 57 
11.2 Reportable Events ............................................................................................................. 45 58 
11.3 Relationship of Adverse Event to Study Device  ................................................................ 46 59 
11.4 COVID -19 Transmission ..................................................................................................... 47 60 
11.5 I ntensity of Adverse Event  ................................................................................................ 47 61 
11.6 Coding of Adverse Events  ................................................................................................. 48 62 
11.7 Outcome of Adverse Events .............................................................................................. 48 63 
11.8 Reportable Device Issues  .................................................................................................. 49 64 
11.9 Timing of Event Reporting  ................................................................................................ 49 65 
11.10 Stopping Criteria  ............................................................................................................. 50 66 
11.11 Independent Safety Oversight  ........................................................................................ 51 67 
11.12 Definition of a Data Breach  ............................................................................................. 51 68 
Chapter 12  Miscellaneous Considerations  ............................................................................. 52 69 
12.1 Prohibited Medications, Treatments, and Procedures ..................................................... 52 70 
12.2 Participant Withdrawal  ..................................................................................................... 52 71 
12.3 Confidentiality  ................................................................................................................... 52 72 
Chapter 13  Statistical Consideration  ..................................................................................... 53 73 
13.1 Statistical and Analytical Plans  .......................................................................................... 53 74 
13.2 Statistical Hypotheses  ....................................................................................................... 53 75 
13.3 Design and Randomization  ............................................................................................... 53 76 
13.4 Sample Size  ....................................................................................................................... 53 77 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 15 of 60 
  13.5 Outcome Measures ........................................................................................................... 54 78 
13.6 Safety Analyses  ................................................................................................................. 55 79 
13.7 Baseline Descriptive Statistics ........................................................................................... 55 80 
13.8 Device Issues ..................................................................................................................... 56 81 
Chapter 14  Data Collection and Monitoring  .......................................................................... 57 82 
14.1 Case Report Forms and Device Data  ................................................................................. 57 83 
14.2 Study Records Retention  .................................................................................................. 57 84 
14.3 Protocol Deviations  ........................................................................................................... 57 85 
Chapter 15  Ethics/Protection of Human Participants  ............................................................ 58 86 
15.1 Ethics Standard  ................................................................................................................. 58 87 
15.2 Institutional Review Boards  .............................................................................................. 58 88 
15.3 Informed Consent Process  ................................................................................................ 58 89 
Chapter 16  References  .......................................................................................................... 60 90 
 91 
  92 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 16 of 60 
  Chapter 1  Background  93 
 
 94 
A major impediment to maintaining blood glucose (BG) control in Type 1 diabetes (T1D) is missed 95 
meal boluses, which has been associated with significantly highe r HbA1c levels .1  While the 96 
advent of the artificial pancreas (AP) offers promise  of safe reductions in HbA1c, our research 97 
group  previously found that the AP only partly compensates for missed prandial insulin2— 98 
demonstrating that some form of meal announcement is ne cessary for good BG control, even 99 
with current  AP systems.  One way to automate this process is by having an AP system that is 100 
able to determine the usual timing of meals for a given individual and provides a small priming  101 
dose  of insulin at this time— a process referred to as meal anticipation.  We previously tested an 102 
AP system that was programmed t o anticipate physical activity and successfully reduce d insulin 103 
delivery during the time of usual exercise.3  We have also recently tested a new artificial pancr eas 104 
system composed of a robust Model Predictive Controller called the RocketAP. We now propose 105 
to test functionality of a module in RocketAP with anticipation  of meal ingestion.      106 
In the current study, we are testing this Rocket AP system for BG respons e to three conditions :  107 
1. FCL: without a meal anticipation module and without announced carbohydrate  108 
2. FCL+: using a meal anticipation module without announced carbohydrate, and  109 
3. HCL: without a meal anticipation module with announced carbohydrate . 110 
We will test this system in up to 18 adults with T1D.  Participants will first be asked during a 4- 111 
week period prior to the main study to eat breakfast and dinner at approximately the same time 112 
for 4 -5 times a week to entrain the system regarding  when these meals are anticipated.  113 
Participants  will then be admitted to the in-person study and will be started on the RocketAP 114 
with approximat ely three 24 -hour periods use of the three conditions described above, in 115 
random order, all implemented on the DiAs platform  (MAF 2109).  As an assessment of the 116 
efficacy of the system in maintaining BG control, p articipants will be followed for approximately 117 
24 hours of use of each of three conditions  noted above (FCL, FCL+ and HCL) .   As an assessment 118 
of safety (and efficacy), t hey will also be followed when a meal is consumed at a later time  than 119 
expected  (dinner will be  consumed approximately  2 hours  later than anticipated  dinner time ) as 120 
well as when a meal is not anticipated to occur at all (participants will receive a lunch which the 121 
system has not been anticipated to expect ).  Our primary outcome will be one of efficacy in 122 
assessing BG control  (TIR 7 0-180 mg/dL)  in the absence of carbohydrate announcement when  123 
the new meal anticipation module  is on (FCL+) vs. off  (FCL) . Additional assessments  of BG control 124 
will be made 1) comparing when the re is no  meal anticipation model and carbohydrate  content 125 
is announce d (HCL) vs. when carbohydrate content is not announced  (FCL+ ), and 2) assessing the 126 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 17 of 60 
  safety of the system by having dinner  later than the usual time —to ensure that this does not 127 
result excess insulin delivery and hypoglycemia, and 3) how  the system responds to a lunch that 128 
has not been entrained  or anticipated  during each of the 3 conditions (FCL+ , FCL without 129 
announced carbohydrate  and during HCL with announced carbohydra te).   130 
We hypothesize that  performances of  Rocket AP with meal antic ipation  (FCL+) will result in 131 
significant improvement over not using the meal anticipation module (FCL) and without risk of 132 
significant hypoglycemia when meals are consumed later than expected.  We expect that this will 133 
constitute an important step toward having a fully automated  AP system.  134 
 
 135 
The purpose of this study is to  test the meal anticipation module on the Rocket AP closed loop 136 
algorithm , assessing efficacy and saf ety. We will target  completion of up to 36 adults  in a 137 
randomized cross -over trial, comparing blood glucose time in range 70 -180 mg/dL following 138 
meals  with and without the meal anticipation module in use  (FCL+ vs FCL) , and comparing to a 139 
system with carb a nnouncement instead of a meal anticipation module (HCL).   We will further 140 
assess safety when dinner is consumed later than usual  and when a lunch is consumed without 141 
having been entrained in the meal anticipation module.  142 
 
 143 
We will consent up to 60 participants,  ages 18- 70 years , with a goal to have up to 36 participants 144 
complete the trial . The study will be performed overnight at a local hotel /rent al h ouse 145 
(heretofore referred to as “hotel”). Enrollment in the Pilot Study will proceed with the goal of 146 
completing 1 -3 participants. This admission will be up to 2 days will be in a hotel/rented house .   147 
 Recruitment and S creening  148 
Participants will be recruited from the UVa Center for Diabetes Techno logy registry, social media 149 
advertisements, physician /health care provider  contacts at diabetes clinics in Virginia. Potential 150 
participants will be informed of the study and will be encouraged to ask the study team questions  151 
about their study participation . Participants will provide written informed consent.   The 152 
screening visit may be performed by  telephone, video conferencing  or in person .   153 
 CGM Data Collection  154 
Following study enrollment , participants will be trained in use of the Dexcom G6 system , 155 
provided with adequate study supplies and have a Dexcom sensor placed.  This training may be 156 
completed via  video conferencing, with supplies sent to the participant  in advance of the call.  157 
This study visit will be followed by 4 weeks of CGM and pump data collection at the participant’s 158 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 18 of 60 
  home/usual routine.  Participants will be asked to have breakfast and dinner at approximately 159 
the same time at least 4 -5 times per week during this period.  160 
Partic ipants will then be randomized to  the order that the y experience the three controller 161 
approaches (for 24 hours each): 1)  with out the meal anticipation module and without 162 
carbohydrate announcement (FCL), 2) with the meal anticipation module on and without 163 
carbohydrate announcement (FCL+), o r 3) with out the meal anticipation module on and with 164 
carbohydrate announcement (HCL).  This will be performed using t hree  permuted blocks of 6. 165 
 Study Hardware/Software 166 
The study itself will involve use of the DiAs prototy ping platform (MAF 2109), connected  to a 167 
Tandem t:AP research pump and a Dexcom G6 sensor, and implementing Rocket AP with  or 168 
without  the meal anticipation module .  Upon arrival at the hotel, participants will be instructed 169 
in how to use the Tandem research pump as well as the UVa AP system, including stopping the 170 
system and bolusing for food.  171 
 Timing of UVa Artificial Pancreas Use  172 
Upon arrival to hotel , participants will have a 12+ hour stabilization period.  The participant will 173 
be connected to a Tandem research pump connected to the UVa DiAs platform and their Dexcom 174 
G6 Transmitter will be linked with DiAs  on the morning of Day 1 . Participants will then be taught 175 
how to use DiAs in this configuration . The research pump will be programmed  with the 176 
individual’s usual insulin parameters. Participants will have their blood sugar managed through 177 
this system during the entirety of the time at hotel . 178 
 Study Controller  Sessions 179 
Order and  timing  of controller sessions : During the hotel stay, participants will have three  180 
separate 24-hour periods during which they will receive three approaches to BG management (in 181 
random order):  1) without the meal anticipation module and without carbohydrate 182 
announcement (FCL), 2) with the meal anticipation module on and without carbohydrate 183 
announcement (FCL+), or 3) with out the meal anticipation module on and with carbohydrate 184 
announcement (HCL).   The timing and potential order of these sessions is shown in Figure 1.  185 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 19 of 60 
   186 
Figure 1:  Timeline and randomized order of the Stud y Controller  Sessions  187 
During these 24 -hour periods participants will be followed for the experimental meals as part of 188 
the Study Controller Sessions to compare blood glucose control using these three different 189 
approaches to insulin management for carbohydr ate control (Figure 1). These study meals 190 
include a late dinner timed later than the participant’s usual dinner time (to assess how the meal 191 
anticipation module handles  a late meal) , a lunch at a time when the system has not been 192 
entrained to expect it  and a breakfast at the participant’s usual breakfast time (see Figure 2).  193 

CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 20 of 60 
   194 
Figure 2:  Timeline of Study Controller Sessions and Study Meals  195 
The primary outcome will compare the percent time CGM is between 70 and 180 mg/dL after 196 
breakfast , starting at the time of breakfast and lasting approximately 5 hours afterwards (until 197 
noon) .  For study meals, participants will consume structured breakfast, lunch and dinner (with 198 
identical protein, fat, and carbohydrate content on each of the days).  During the FCL and FCL+ 199 
sessions, participants will not announce the carbohydrate content in meals (and all additional 200 
insulin will be delivered by the AP system, without and with meal anticipation, respectively), 201 
while during the HCL session, participants  will use insulin dosing via normal carbohydrate 202 
announcement and the DiAs CGM -based bolus calculator.  Study staff who will be present will 203 
include nursing staff  and technical staff ; a study physician will be available either on -site or 204 
nearby off -site at  all times . Hyperglycemia and hypoglycemia treatment protocols will be 205 
followed per CDT protocol. We anticipate more significant cases of hyperglycemia during dinner s 206 
managed without carbohydrate announcement ; participants will be encouraged to drink large  207 
amounts of non -caloric beverages, particularly after these meals . 208 
The UVa AP  system s will be  initiated  upon arrival to the hotel the morning  before the first of the  209 
Controller  Sessions . UVa CDT study staff will monitor CGM output continuously and manage 210 
glucose  control issues.  At the end of the hotel stay , the participant will return to their  home 211 
insulin management .  212 Closed Loop
Bkfst
9am 1pm 9am TBDLate dinnerTIR TIR %<70
Expected dinner Expected breakfast
TBD
Noon Noon 4pmTIR
Expected dinner Expected breakfast
TBDlunchbolusController A
Midnight Midnight
Controller C Controller BStabiliza�on
LunchLunch
LunchTIR
9amNoonFriday Saturday
Sunday MondayTBD
TBDFixed lunch
Fixed lunch Fixed lunch Expected breakfastExpected dinnerMain Study N =36
Late dinner%<70BkfstTIR
Late dinner%<70
BkfstTIR
TBDTBD+2h4PM4PM
4PM
TBD+2h
TBD+2hThursday
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 21 of 60 
  
 
 213 
Before discharge from the hotel, all study devic es will be turned in to study staff for device 214 
download  and the participants will be placed on usual diabetes management. 215 
 
 216 
If the CGM signal becomes unavailable for more than 20 minutes consecutively, closed loop will 217 
not operate to auto matically adjust insulin.  If the CGM is not connected, the system will revert 218 
to usual function of the pump and deliver insulin with the insulin dosing parameters programmed 219 
in the system for that individual. Resumption of c losed -loop control  will occur  automatically once 220 
CGM signal is available again.  221 
If the study system is unable to maintain pump connectivity , the pump will automatically revert 222 
to pre -programmed basal insulin delivery after 30 minutes without any need for instruction from 223 
the user.  224 
 
 225 
 Study Participants  226 
Enrollment in the Pilot Study will proceed with the goal of completing 1-3 participant s. Up to 6 227 
participants m ay sign the consent  form.  228 
Enrollment in the Main S tudy will proceed with the goal of completing up to 36 participants .  Up 229 
to 60 participants may sign the Main Study consent form .   230 
 Clinical Sites  231 
The study will be performed at the University of Virginia, with screening procedures taking place 232 
either virt ually , at the Clinical Research Unit , or at local hotel.   233 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 22 of 60 
  Chapter 2  Study Devices  234 
 
 235 
The study system s will utilize  the Tandem t:AP research pump  connected to the UVa DiAs system 236 
run on a dedicated external smart phone , running the Rocket AP control algor ithm with the meal 237 
anticipation module (which will be turned on or off, depending on the Controller session, with 238 
the order of these sessions determined randomly) . 239 
 
 240 
The study CGM will include Dexcom G6 transmitter and sensors. The CGM sensor is viable for 10 241 
days.  242 
 
 243 
Study participants will use their personal glucometer  during the study .  A study glucometer will 244 
be provided in the event that the participant’s glucometer cannot be downloaded.   245 
 
 246 
Blood ketone levels will be measured during the hotel admission with the use of the Abbott 247 
Precision Xtra meters and strips in accordance with the manufacturer’s labelling . The blood 248 
glucose meter component of the Precision Xtra D evice will not be used.   249 
 
 250 
Device serial numbers will be recorded and use of equipment will be tracked.   251 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 23 of 60 
  Chapter 3  Study Screening  252 
 
 253 
Pilot Study:  Enrollment goal in the Pilot Study will b e to complete 1-3 participant s. Up to 6 254 
participants may sig n consent  forms.  255 
Main Study:  Enrollment in the study will proceed with the goal of completing up to 36 256 
participants .  Participants will initially be randomized for the order of their 3 experimental meals 257 
use during the study.  Up to 60 participants may sign the consent  form.  258 
 
 259 
Before consent has been obtained, participants will be asked inclusion/exclusion criteria 260 
questions during pre-screening  to determine study eligibility. Before completing any procedures 261 
or collecting any data that are not part of usual care, written informed consent , when applicable) 262 
will be obtained. Potential eligibility may be assessed as part of a routine -care examination.   263 
A participant is considered enrolled when the informed consent form has been signed  by the 264 
participant and the study team . 265 
Consent ing procedures and documentation is defined in section 15.3.  266 
 
 267 
After informed consent has been signed, a potential participant will be evaluated for study 268 
eligibility through the elicitation of a medical history, performance of a physical examination 269 
by licensed  personnel , and pregnancy testing (if applicable) to screen for exclusionary medical 270 
conditions.   If done remotely, a  physical exam documented in the prior 18 months can suffice for 271 
the physical exam  but will not serve as an exclusionary criterion  if not a vailable . If done remotely, 272 
participants may self -report height and weight. Individuals who do not initially meet study 273 
eligibility requirements may be rescreened at a later date per investigator discretion.  274 
 
 275 
The participants must meet all of the following inclusion criteria in order to be eligible to 276 
participate in the study.  277 
1. Age ≥1 8.0 and ≤70 years old  at time of consent  278 
2. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one  year  279 
3. Currently using insulin for at least six months  280 
4. Currently using insulin pump for at least three months   281 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 24 of 60 
  5. Using insulin parameters such as carbohydrate ratio and correction factors consistently on 282 
their pump in order to dose insulin for meals or corre ctions  283 
6. Access to internet and willingness to upload data during the study as needed  284 
7. For females, not currently known to be pregnant  or breastfeeding  285 
8. If female and sexually active, must agree to use a form of contraception to prevent pregnancy 286 
while a par ticipant in the study.  A negative serum or urine pregnancy test will be required 287 
for all females of child bearing potential. Participants who become pregnant will be 288 
discontinued from the study. Also, participants who during the study develop and express 289 
the intention to become pregnant within the timespan of the study will be discontinued.  290 
9. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the 291 
study CGM is in use  292 
10. Willingness to use the UVa closed -loop  system throughout study admission  293 
11. Willingness to use lispro (Humalog ) or aspart (Novolog) during the study admission. 294 
12. Willingness not to start any new non -insulin glucose -lowering agent during the course of the 295 
trial (including metformin, GLP -1 agonists, pramlintide, DPP -4 inhibitors, biguanides, 296 
sulfonylureas and naturaceuticals)  297 
13. Willingness to eat at least 1  g/kg  of carbohydrate per day during the hotel  admission  298 
14. Willingness to reschedule if placed on oral steroids  299 
15. An understanding and willingness to follow the protocol and signed informed consent  300 
16. Willingness to comply with COVID -19 precautions as defined by the study team. (Study team 301 
will reference section  10.3.)  302 
17. Willingness to provide a c opy of COVID -19 vaccination record, if available.  303 
 
 304 
The participant must not have any exclusion criteria in order to be eligible to participate in the 305 
study.  306 
1. History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment  307 
2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior 308 
to enrollment  309 
3. Pregnancy or intent to become pregnant during the trial  310 
4. Currently being treated for a seizure dis order  311 
5. Planned surgery during study duration  312 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 25 of 60 
  6. Treatment with any non- insulin glucose -lowering agent (including metformin, GLP -1 313 
agonists, pramlintide, DPP -4 inhibitors, SGLT -2 inhibitors, biguanides, sulfonylureas and 314 
naturaceuticals)   315 
7. A known medical condi tion that in the judgment of the investigator might interfere with 316 
the completion of the protocol . 317 
8. Use of an automated insulin delivery mechanism that is not downloadable by the subject 318 
or study team  319 
9. Known contact with a COVID -19 positive individual within 14 days of the hotel/rent al 320 
house  stud ies. 321 
 
 322 
The participant will be evaluated for study inclusion and exclusion eligibility  after the informed 323 
consent form has been signed by the participant and the study team .  324 
Individuals who do not initially meet study eligibility requirements may be rescreened at a later 325 
date per investigator discretion. 326 
1. Demographics  327 
o Date o f birth 328 
o Gender  329 
o Race  330 
o Ethnicity 331 
2. Medical History  332 
o Duration of disease (number of years)  333 
o Current insu lin pump model  334 
o History of CGM use  335 
o Current treatment  336 
i. Basal rates  337 
ii. Carbohydrate ratios  338 
iii. Insulin sensitivity factors  339 
iv. Target glucose  340 
v. Average daily insulin  341 
o History of diabetic ketoacidosis  342 
o History of severe hypoglycemia  343 
o History of seizures  344 
o Loss of consciousness  345 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 26 of 60 
  • Surgical history  346 
• Allergies  347 
• Concomitant medications  348 
3. Physical Examination – If performed remotely, a  historical history and physical report 349 
within 18 months of screening appointments may be used  but is not required for 350 
eligibility . If vitals are not available, may include self -reported weight and height.  351 
o Weight  352 
o Height  353 
o Blood pressure  354 
o Temperature  355 
o Heart Rate  356 
4. Screening Labs  357 
o Hemoglobin A1c point of care  358 
o Urine or serum pregnancy test for all women  of child bearing potential  359 
Screening procedures will last approximately 1 -2 hours. Screening can be performed via 360 
telephone or video conference.  Once all results of the screening evaluations are available, a 361 
decision will be made to determine the participant ’s eligibility for the study or if one or more part 362 
of the screening will have to be repeated. If at the first screening or repeat screening an 363 
exclusionary condition is identified, the participant will be excluded from participation with 364 
follow up and ref erred to their primary care physician as needed. The study physician may elect 365 
to rescreen participants if their clinical situation changes. Notably, screening is for determining 366 
study eligibility.  Once participants are found to be eligible, they can begi n their data collection 367 
phase  as noted in Pilot Participants or Main Study .  368 
 
 369 
The Demographic Data Survey will be electronically administered once eligibility has been met.   370 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 27 of 60 
  Chapter 4  Randomization  371 
Participants will receive the three differen t experimental condition (FCL, FCL+, HCL) in random 372 
order as described below.  373 
 
 374 
Pilot participants will not be randomized but will only use the meal anticipation module with an 375 
experimental  meal without carbohydrate announcement  and a study meal that is later than the 376 
usual entrained timing . 377 
 
 378 
Once eligibility is met  and the Data Collection Phase ( CGM/ Meal Entrainment ) period is 379 
complete , the participant may continue to randomizati on. Screening failures and study dropout 380 
participants may be replaced. Randomization will determine the order of the Study Controller  381 
Sessions , with potential order as shown in Figure 1 .  Randomization will occur via permuted 382 
blocks of 6.    383 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 28 of 60 
  Chapter 5  Study Equipment Training  384 
Equipment training may begin at arrival to hotel after UVa AP system has been pu t in place.   The 385 
purpose of this training is to introduce the study insulin pump and study CGM to the participant.  386 
The participant’s insulin parameters will be programmed into th eir study insulin pump by two 387 
research staff. Subjects will then switch to the study insulin pump. The participant’s personal 388 
pump and infusion site will be removed.  389 
The participant will have the insulin pump and sensor on them at all times. Study supplied phones 390 
will be used if DiAs is the system utilized and otherwise upon participant request.  391 
 
 392 
A study CGM will be provided to all participants at the training session. The participants will be 393 
provided with CGM equipment and instructed to use t he study CGM on a daily basis. If the 394 
participant has  prior use of the CGM , re-training will be specific to the individual.  The study team 395 
may elect to have less frequent CGM users watch the Dexcom online training videos 396 
(https://www.dexcom.com/training -videos)  to assist in the training session .  Study staff t raining 397 
may include review of study CGM in real- time to make management decisions and how to review 398 
the data after an upload for retrospective review. Study staff wil l specifically identify how alarms 399 
are set using the app and the frequency that these alarms will repeat.  400 
The participants personal CGM will be discontinued. The participants will be observed placing the 401 
sensor and will learn/review how to access the CGM t race via the DiAs phone or the Tandem 402 
research pump, as needed . The participants will be asked to perform fingerstick blood glucose 403 
measurements (if needed) in accordance with the labelling  of the study CGM device.  404 
An electronic copy of the CGM user’s guide will be provided for the participants to read . The 405 
study team will be sure that the participants will leave the training session  knowing how to use 406 
proper use the CGM. The study team will be available for any ques tions.  407 
Participants will have the option of using their personal smartphone or receive a study 408 
smartphone to use in order to collect the data from the devices.  If the participant elects to use a 409 
personal device, the Dexcom app will be downloaded to their p hone in order to monitor the 410 
participant’s CGM values and alerts in real- time may be used.  411 
 
 412 
All participants may  be asked to wear an activity tracker (e.g. Fitbit) during the entire study (home 413 
and hotel admissions) to record information ab out movement and heart rate though not an 414 
endpoint in this study.  415 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 29 of 60 
  
 
 416 
The study team will be responsible monitoring and managing the study insulin pump during the 417 
hotel admission s. The participants may be provided a quick overview  on its fu nctionality if they 418 
understand the equipment.  419 
 Study Insulin Pump Topics   420 
The study team will assist the participant in study pump infusion site initiation and will start the 421 
participant on the study pump. The study pump will be programmed with the participant’s usual 422 
basal rates and pump parameters. The participant’s personal pump will be removed.  423 
The participant will be instructed infusion site initiation, cartridge/priming procedures, setting 424 
up the pump, charging the pump, navigation through menus, bolus procedures including  entering 425 
meal s, stopping a bolus,  etc. 426 
 Other Issues  427 
The participant will be instructed to  notify study staff  if they experience any issues with the study 428 
devices during the hotel admission. Staff will be present in the event that if insulin is delivered 429 
by any means other than the study pump (e.g. injection of subcutaneous insulin via syringe in the 430 
event of infusion site failure). If insulin is delivered by any means other than the study pump, the 431 
study team  will be instructe d to turn off closed -loop mode  for approximately four hours.  432 
The participant will also be asked to alert the study clinical staff for technical issues with the 433 
Tandem research pump and/or the DiAs system, including use of the study pump and study CGM 434 
(open  loop mode) during periods of component disconnections or technical difficulties.  435 
A glucagon emergency kit will be available. Participants who currently do not have one will be 436 
asked to obtain a prescription for the glucagon emergency kit.  437 
Glycemic Treatment Guidelines (Chapter 8 ) will be available for staff use  during the study  438 
admissions . 439 
 Optimization of Insulin Pump Settings  440 
Data -driven optimization of pump setti ngs can occur any time prior to the hotel admission, 441 
particularly if the participant contacts the study physician due to concerns about their pump 442 
settings due to recurring hypo- or hyperglycemia. No pump settings changes can occur during 443 
closed loop testi ng.  444 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 30 of 60 
  Chapter 6   Pilot Study  445 
In order to optimize the flow of the study visits during the Main Study , we will perform a Pilot 446 
Study with up to three pilot participants at a local hotel  or rent al house . Participants  and staff  447 
will adhere to the COVID  -19 Mitigation Plan as outlined in Section 10.3.  The duration of the pilot 448 
admission will be approximately 24  hours with the intent of collecting appropriate safety data.  449 
Pilot study participants are eligible to enroll in the Main Study.  450 
 
 451 
Participants will wear the study CGM at home for approximately  28 days.  If currently using a 452 
Dexcom G6, up to 30 days of data may be obtained from the partic ipant’s personal CGM and 453 
pump.   The investigators may still ask G6 users to complete this run -in phase at their discretion.   454 
 
 455 
For the pilot study, there will be at least two study staff present at all times at the study site, at 456 
least one of whom will be clinical staff (e.g. nurse, physician, nurse practitioner). There will be a 457 
physician available either on -site or off-site within a n approximate  20-minute drive at all times.    458 
In addition, one of the study medical physicians and one senior engineer will be on call during 459 
the entire admission. Glucagon for the emergency treatment of hypoglycemia will be available 460 
on-site.  461 
 
 462 
Pilot participants will be contacted by the study team appr oximately 24-48 hours prior to the 463 
hotel ad mission to verify the following information:  464 
• Inquire about any changes to the participant’s medical history  465 
• Study equipment (e.g. CGM and activity tracker) initiation has occurred  466 
• Determine pump profile(s) the par ticipant uses on certain days  467 
• New CGM sensor has been placed approximately 24-72 hours prior to admission  for 468 
proper warm- up 469 
• Verify with the participant  that the goal CGM reading at time of arrival is less than 2 00 470 
mg/dL; this may require contact with the study physician prior to arrival on the day of the 471 
study visit  472 
• Should any concerns regarding medical history, pump information, or unforeseen issues 473 
arise, the admission will be cancelled for that participant at the discretion of the 474 
investigator  475 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 31 of 60 
  
 
 476 
For the pilot study, one to two  participant s will be assessed at a time.  The participant  will arrive 477 
at the hotel or rent al house on the first day of the admission.  The study team will perform vital 478 
signs , and any changes to the participant’s medical history.  Any changes to medical history will 479 
be communicated to the medical physician to ensure continued eligibility and participation.   480 
A urine pregnancy test will be collected  if relevant . The test must be negative for the participant 481 
to continue with the study.  482 
The subject’s CGM reading , and ketone concentration will be recorded. In the event that the 483 
participant’s CGM reading is not between 80 -250 mg/dL or ketone concentration is ≥0.6 mmol/L 484 
prior to initiation  of the UVa AP system , the study physician may recommend  additional insulin 485 
dosing according to the participants’ usual doses . Study physician may elect to cancel 486 
participant’s participation in the hotel admission if concerned about their medical safety.  This 487 
participant will not be replaced.  488 
The participant’s home  insulin pump will be discontinued,  and the study Tandem research  insulin 489 
pump will be initiated.  The study team will ensure the proper function of the CGM, insulin pump, 490 
and activity tracker. The goal will be to initiate Closed -Loop  Control by approximately lunch time , 491 
running the Rocket AP system  on the DiAs platform .  492 
The CGM used in the study is FDA -approved for the non- adjunctive measurement of blood 493 
glucose (i.e. the CGM reading can be used for insulin dosing decisions). The CGM readings will be 494 
the primary source of blood glucose values .  There are no protocol fingerstick blood glucose 495 
measurements other than at times of CGM calibration (if necessary) and if directed by the study 496 
team. Fingers tick blood glucose measurements may be taken whenever participants experience 497 
symptoms, if the CGM glucose is suspected to be erroneous, or any time the participant would 498 
like to be reassured . 499 
 
 500 
Participants will eat a structured dinner at approximately 6 -7 pm during the admission. The 501 
participant will not announce carbohydrate ingestion, allowing testing of the Rocket AP 502 
controller. Throughout the Pilot study, the participant will remain in closed loop mode .  503 
Participants will consume approximately  30-90 grams of carbohydrates  at each meal. The study 504 
participant  will determine the quantity of carbohydrates in each meal.  Staff will separately record 505 
the calculated carbohydrate count. FCL and FCL+ will be tested during the pilot.   Staff will 506 
continue to follow the Glycemic Treatment Guidelines detailed in Chapter 8.  507 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 32 of 60 
  
 
 508 
Participants will be free to engage in low -intensity activity (i.e. walking) during the admission . 509 
Participants will enjoy  quiet activities in the  evening.  510 
 
 511 
Discharge will be at approximately 8 a.m. If the CGM values are above 300 mg/dL and ketone 512 
values are >0.6 mmol/L, the study team will check the insulin pump infusion site and correction 513 
insulin will be administered per study physician judgement v ia the subject’s insulin pump.   A 514 
qualified clinical study team member (e.g. MD, NP, CDE) will assess and discuss the transition 515 
back to usual care with the study participant.    516 
Participants will be asked to continue monitoring ketone levels for 24 -48 hours after the hotel 517 
admission  if ketones were present at time of discharge. Urine ketone supplies may be provided  518 
for this testing.  519 
 
 520 
Approximately 24-48 hours after the hotel admission , the study team will contact the participant 521 
via phone/email/text /text to assess adverse events, adverse device effects, and device issues . 522 
 523 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 33 of 60 
  Chapter 7   Main Study  524 
 
 525 
Main Study participants will participate in hotel admission. Each admission  will be up to 526 
approximately 92 hours  in duration . Participants and staff will adhere to the Center for Disease  527 
Control and Prevention  (CDC) and local guidance COVID  -19 Mitigation Plan effective at the time 528 
of the study.   529 
 
 530 
Participants who are not familiar with the Dexcom G6 CGM will have a run -in phase in which they 531 
wear the equipment at home for approximately 14 days  to ensure proper use of the equipment .  532 
All participants will wear the CGM at home for approximately 28 days, with instructions to eat 533 
breakfast and dinner at approximately the same time 4 -5 days each week. The timing of the 534 
breakfast will be requested to be at or before 8 am and the timing of the dinner will be requested 535 
to be between 6 -9 pm .  If currently using a Dexcom G6, up to 30 days of data may be obtained 536 
from the participant’s personal CGM  and pump.  If participant reports consistent timing of meals 537 
in the 30 days before enrollment, these data may  be used instead of the CGM/Meal Entra inment 538 
period  at the discretion of the investigators . The investigators may ask current Dexcom G6 CGM 539 
users to complete this run -in phase at their discretion.  Data -driven optimization of insulin dosing 540 
parameters can occur at any time d uring and immediately after the CGM/Meal Entrainment 541 
period.  542 
 
 543 
There will be at least two study staff present at all times at the study site  when the investigational 544 
device is active , with at least one of whom will be clinical staff (e.g. n urse, physician, nurse 545 
practitioner). There will be a physician at the hotel  or nearby on call during the study  at all times.  546 
In addition, at least  one senior engineer will be on call during the entire admission. Participants 547 
will be remotely monitored by  at least one  study team  member  using a web -based remote 548 
monitoring system that has been previously established for DiAs .  The web -based remote 549 
monitoring system will display real- time insulin delivery, CGM and other system information to 550 
allow for patient safety monitoring.    In addition, study team members will be trained in all 551 
protocol and Glycemic Treatment Guideline procedures (Chapter 8 ). The closed -loop system will 552 
be managed by the participant with study -staff supervision, particularly at the time of insulin 553 
boluses .  Glucagon for the emergency treatment of hypoglycemia will be available on -site.  554 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 34 of 60 
  
 
 555 
Participants will be contacted by the study team approximately 24-72 hours prior to each  hotel 556 
admission  if most recent contact with the study participant exceeds 10 days. The study team will 557 
verify the following information:  558 
• Inquire about any changes to the participant’s medical history  559 
• Adhere to relevant sections of 10.3 COVID -19 Risk Mitigation Plan   560 
• Study equipment (e.g. CGM and activity tracker) initiation has occurred  561 
• Determine pump profile(s) the participant uses on certain days  562 
• New CGM sensor has been placed approximately 24 -72 hours prior to admission for 563 
proper warm- up 564 
• Verify with the subject that the goal CGM reading at time of arrival is less than 2 00 565 
mg/dL; this may require contact with the study physician prior to arrival on the day of the 566 
study visit  567 
• Should any concerns regarding medical history, pump information, or unforeseen issues 568 
arise, the admission will be cancelled f or that participant at the discretion of the 569 
investigator  570 
 
 571 
Day 0 Arrival  572 
Participants will arrive at the hotel on the first day of the admission.  The study team will inquire 573 
about any changes to the participant’s medical history.  Any c hanges to medical history will be 574 
communicated to the medical physician to ensure continued eligibility and participation.   575 
A new CGM sensor will be placed if the sensor has  not been changed within the last 24 -48 hours.  576 
Participants will be provided unst ructured dinner (no meal -time restrictions ). Participants are on 577 
their home devices overnight and, therefore , no study staff are required to be present.  578 
Day 1 Morning  579 
The study team will perform vital signs. The subject’s CGM reading,  and ketone concentrat ion 580 
will be recorded. In the event that the participant’s CGM reading is not between 80 -250 mg/dL 581 
or ketone concentration is ≥0.6 mmol/L prior to initiation of the UVa artificial pancreas system, 582 
the study physician may recommend  additional insulin dosing according to the participants’ usual 583 
doses. Study physician may elect to cancel participant’s participation in the hotel admission if 584 
concerned about their medical safety.  This participant will not be replaced. A urine pregnancy 585 
test will be collected for  female participants of childbearing age within 24 hours prior to 586 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 35 of 60 
  transitioning to the AP Controller. The test must be negative for the participant to continue with 587 
the study.  588 
 589 
The participant’s home insulin pump will be discontinued,  and the study insulin pump will be 590 
initiated. The insulin site will be changed   and the participants may use the Tandem t:AP2 pump 591 
without  the DiAs platform for basal delivery until transition to AP. The study team will ensure the 592 
proper function of the CGM, insulin pump, and activity tracker.  593 
The CGM used in the study is FDA -approved for the non- adjunctive measurement of blood 594 
glucose (i.e. the CGM reading can be used for insulin dosing decisions). The CGM readings will be 595 
the primary source of blood glucose values.  There are no protocol fingerstick blood glucose 596 
measurements other than at times of CGM calibration (if necessary) and if directed by the study 597 
team.  Fingerstick blood glucose measurements may be taken whenever participants experience 598 
sympt oms, if the CGM glucose is suspected to be erroneous, or any time the participant would 599 
like to be reassured. Glycemic Treatment Guidelines to be used during the hotel admission are 600 
defined in a separate document.  601 
 
 602 
Participants will eat struct ured study meals during the admission, with the same amount of 603 
carbohydrate, protein , and fat for the same meals (breakfast, lunch, dinner) on different days 604 
(days 1, 2, and 3) . Meal content may differ on the same day.  The dinners will occur approximately  605 
2 hours after the time that is usual for the participant from the Data Collection Phase (CGM/Meal 606 
Entrainment period, defined as the median time of recorded meals between 6 and 8pm).  The 607 
breakfasts will occur at approximately the time that is usual for the participant from the Data 608 
Collection Phase (CGM/Meal Entrainment period, defined as the median time of recorded meals 609 
between 5am and 8am) , and the lunches will occur at approximately noon (see Figure 2).   610 
Participants will consume approximately  30-90 grams of carbohydrates at each meal. The study 611 
participant will determine the quantity of carbohydrates in each meal and will enter this 612 
information into the insulin pump with staff supervision during HCL . Staff will separately record 613 
the calculated carbohydrate count at each meal.  The carbohydrate content of the system will 614 
only be announced during the HCL Controller period.  During HCL, correction doses of insulin will 615 
also be calculated at the time of meals. During FCL and FCL+, study staff will be monitoring the 616 
closed -loop system as usual to identify insulin administration in the setting of postprandial 617 
hyperglycemia. Staff will continue to follow the Glycemic Treatment Guidelines detailed in 618 
Chapter 8.   Snacks with carbohydrates will not be allowed  unless for the treatment of low blood 619 
sugars. No n-carbohydrates snacks are allowed throughout the protocol.  Blood gl ucose levels will 620 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 36 of 60 
  be followed via continuous glucose monitor and glucose values will be managed by the AP system 621 
as usual.  622 
 
 623 
Participants will be free to engage in low -intensity activity ( i.e. walking) during the hotel 624 
admission. Parti cipants may leave the hotel  to be outside, provided they are accompanied by a 625 
study staff member and masking and distancing are observed,  as described in Section 10.3. 626 
Participants will enjoy quiet activities in the evening.  627 
 
 628 
Discharge will be at approximately  4 pm. If the CGM values are above 300 mg/dL and ketone 629 
values are >0.6 mmol/L, the study team will check the insulin pump infusion site and correction 630 
insulin will be administered per study physician judgement v ia the subject’s insulin pump. A 631 
qualified clinical study team member (e.g. MD, NP, CDE) will assess and discuss the transition 632 
back to usual care with the study participant .   Stud y team will reference the Glycemic Treatment 633 
Guidelines.  634 
Participants will be asked to continue monitoring ketone levels for 24 -48 hours after the hotel 635 
admission  if ketones were present at time of discharge. Urine ketone supplies may be provided 636 
for this testing.  637 
 
 638 
Approximately 24-48 hours after the hotel admission, the study team will contact the participant 639 
via phone/email/ text to assess adverse events, adverse device effects, and device issues .  640 
  641 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 37 of 60 
  Chapter 8  Glycemic Treatment Guidelines 642 
The following guidelines will be used for both the Pilot Study and the Main Study  Admissions to 643 
the hotel/rental house.   644 
The study physician will suggest appropriate treatment If CGM is <70 mg/dL or >250 mg/dL, or 645 
ketone test is >0.6 mmol/L at the start of the hotel admission. The study subject may continue 646 
participation in the trial once CGM is between 70 -250 mg/dL and ketone concentration is ≤0.6 647 
mmol/L.    648 
If CGM <60 mg/dL at any time, subjects will be given approximately 8 -16 grams of fast -acting 649 
rescue carbohydrates. Study team will monitor CGM rise and will consider treating again if CGM 650 
<80 mg/dL after approximately 15 -20 minutes. Hypoglycemic treatments can occur at any time 651 
per study physician request.  Glucagon will be available at the study site and will be administered 652 
in the event of loss of consciousness or seizure related to hypoglycemia.   653 
The study team may request fingersticks as needed. Any finge rstick readings obtained will be 654 
addressed the same way as the CGM values.    655 
If CGM is >250 for more than 3 hours or >400 mg/dL at any time, study physician will 656 
be notified,  and ketones will be checked. In addition, insulin administration by the closed -loop 657 
system will be evaluated and infusion sites assessed. If ketone concentration is >0.6 mmol/L, the 658 
study team will check the insulin pump infusion site and consider changing  and correction insulin 659 
will be administered via the subject’s insulin p ump  or subcutaneous as needed.  If subcutaneous 660 
injection is administered, physician will determine if closed -loop control needs to be temporarily 661 
stopped for up to 4 hours.  The study team will monitor CGM changes and ketones will be checked 662 
every 60 minute s until ketone concentration is ≤0.6 mmol/L. If ketone concentration is ≥3.0 663 
mmol/L, the study physician will recommend the appropriate medical treatment.  664 
The study physician will suggest appropriate treatment If CGM is <70 mg/dL or > 300 mg/dL and 665 
ketone test is >0.6 mmol/L at the conclusion of the hotel admission. The study subject may be 666 
discharged home once CGM is between 70 -300 mg/dL and ketone concentration is ≤0.6 mmol/L.    667 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 38 of 60 
  Chapter 9   Testing Procedures  668 
 
 669 
 HbA1c  670 
A blood sample will be obtained at screening to obtain a baseline hemoglobin A1c level. A Blood 671 
test obtained within 2 weeks prior to enrollment ma y be used . 672 
HbA1c level may be measured by study team using the DCA2000, a comparable point of care 673 
device , at time of screening   674 
Labs may be obtained at a local laboratory (e.g. LabCorp) convenient to the participant.  675 
 Pregnancy Test  676 
A serum or urine pregnancy test will be required for women of childbearing  potential at in person 677 
visit and admission.   Test must be  negative to participate in the study.  678 
  COVID -19 Testing (Non- vaccinated participants /staff )  679 
Non -vaccinated participants  and study  staff (research coordinators, technicians, nurses , and 680 
physicians ) will be tested with an FDA authorized COVID -19 test  approximately 72 hours before 681 
starting  the study hotel , and upon admission to the study hotel (main study only) .  Individuals 682 
with COVID -19 positive tests will be excluded from the study.   683 
 Demographic Data Survey  684 
The Demographic Data Survey will be asked at only the screening appointment and will reflect 685 
the status of the participant.    686 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 39 of 60 
  Chapter 10  Risks Associated with Clinical Trial  687 
 
 688 
Risks and Benefits are detailed below. Loss of confidentiality is a potent ial risk; however, data are 689 
handled to minimize this risk . Hypoglycemia, hyperglycemia and ketone formation are always a 690 
risk in participants with type 1 diabetes and participants will be monitored for these symptoms.  691 
 Venipuncture Risks  692 
A hollow needle/plastic tube may  be placed in the arm for taking blood samples  (e.g. external 693 
HbA1c measurements for inclusion criteria) . Blood draws can cause some common reactions like 694 
pain, bruising, or redness at the sampling site.  Less common reactions include bleeding from the 695 
sampling site, formation of a small blood clot or swelling of the vein and surrounding tissues, and 696 
fainting.  697 
 Fingerstick Risks  698 
About 1 drop of blood will be removed by fingerstick for measuring blood sugars and sometimes 699 
HbA1c or other tests. This is a standard method used to obtain blood for routine hospital 700 
laboratory tests.  Pain is common at the time of lancing.  In about 1 in 10 cases, a small amount 701 
of bleeding under the skin will produce a bruise . A small scar may persist  for several weeks . The 702 
risk of local infection is less than 1 in 1000 . This should not be a significant contributor to risks in 703 
this study as finger sticks are part of the usual care for people with diabetes.  704 
 Subcutaneous Catheter Risks (CGM)  705 
Participants using the CGM will be at low risk for developing a local skin infection at the site of 706 
the sensor needle placement . If a catheter is left under the skin for more than 24 hours it is 707 
possible to get an infection where it goes into the skin, wit h swelling, redness and pain.  There 708 
may be bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 709 
risk).  710 
Study staff should verbally alert the participant that on rare occasions, the CGM may break and 711 
leave a small port ion of the sensor under the skin that may cause redness, swelling, or pain at 712 
the insertion site . The participant should be further instructed to notify the study coordinator 713 
immediately if this occurs.  714 
 Risks of Hypoglycemia  715 
As with any person having type  1 diabetes and using insulin, there is always a risk of having a low 716 
blood sugar (hypoglycemia) . The frequency of hypoglycemia should be no more and possibly less 717 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 40 of 60 
  than it would be as part of daily living . Symptoms of hypoglycemia can include sweating, 718 
jitteriness, and not feeling well.  Just as at home, there is the possibility of fainting or seizures 719 
(convulsions) and that for a few days the participant may not be as aware of symptoms of 720 
hypoglycemia.  A CGM functioning poorly and significantly over- readi ng glucose values could lead 721 
to inappropriate insulin delivery.  722 
 Risks of Hyperglycemia  723 
Hyperglycemia is likely because of the study design including unannounced carbohydrate 724 
ingestion.  Also, hyperglycemia and ketonemia could occur if insulin delivery is attenuated or 725 
suspended for an extended period or if the pump or infusion set is not working properly.  A CGM 726 
functioning poorly and significantly under -reading glucose values could lead to inappropriate 727 
suspension of insulin delivery.  728 
 Risks of Device Reus e  729 
Participant will be informed that FDA or relevant national authorities have approved the insulin 730 
pump, CGM, glucometer and ketone meter for single use and that by using them among multiple 731 
patients, bloodborne pathogens (i.e. Hepatitis B) may be spread through the use of multiple 732 
users.  733 
The study CGM system is labelled  for single use only. The sensor (the component of the system 734 
that enters the skin) will be single use only. The transmitter and receiver may be reused during 735 
the study after cleaning the d evice using a hospital- approved cleaning procedure. The transmitter 736 
is attached to the sensor but does not enter the skin and the receiver, if used, is a handheld  737 
device.  738 
The study insulin pump s are labe lled for single -patient use. During the study, this device may be 739 
reused after cleaning adhering to a hospital- approved cleaning procedure. All infusion set 740 
equipment will be single patient use only (infusion set insertion kits, tubing, cartridges etc.) .   741 
The study blood glucose meter and blood ketone mete r are labe lled for single -patient use. 742 
During  the study, these devices may be reused after cleaning adhering to a hospital -approved 743 
cleaning procedure.   744 
 Device Cleaning Instructions  745 
CGM cleaning instructions are provided in the Dexcom G4 P latinum  (Profess ional) Cleaning and 746 
Disinfection manual (current edition) and a similar approach will be applied for the G6 version 747 
used in this study . The transmitter should be cleaned with Clorox Healthcare® Bleach Germicidal 748 
Cleaner or any disinfectant product in a spr ay bottle containing a bleach solution of 6500 parts 749 
per million with the EPA registration number 56392 -7.  The transmitter will be submerged in this 750 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 41 of 60 
  solution and then placed on an absorbent wipe or clean surface.  Two sprays will be dispensed 751 
from the Clo rox cleaner onto each side of the transmitter. A nylon brush will be used to scrub the 752 
transmitter on all sides for 30 seconds.  The transmitter will be placed in the Clorox Cleaner 753 
solution for one minute. Transmitter is then rinsed under flowing tap water for ten seconds. The 754 
transmitter will then be disinfected using a disinfectant product with EPA registration number 755 
56392- 7 using similar procedures as the cleaning process.   756 
Per the pump manufacturer, the insulin pump will be cleaned with a damp lint -free cloth. Use of 757 
household or industrial cleaners, sol vents, bleach, scouring pads, chemi cals, or sharp instruments 758 
are prohibited. The pump should never be submerged in water. If needed, use only a very mild 759 
detergent, such as a bit of liq uid soap wit h warm water. A soft towel will be used to dry the pump.  760 
The glucometer is cleaned and disinfected with two separate Super Sani- Cloths (EPA number 761 
9480- 4). The entire surface will be cleaned, making sure the surface stays wet for 2 minutes. This 762 
step is r epeated with a clean cloth for disinfecting the device.  763 
The Precision Xtra User’s Guide suggests that healthcare professionals use 10% bleach, 70% 764 
alcohol or 10% ammonia to clean the device.  765 
Equipment that touches intact skin will be cleaned with ethyl o r isopropyl alcohol (70 -90%), 766 
quaternary ammonium germicidal detergent (i.e. Cavicide, EPA number 46781) or household 767 
bleach. The contact time on the surface depends on the method used to clean the equipment. 768 
Cavicide requires three minutes on the surface of the equipment. Clorox Germicidal Bleach Wipes 769 
require two minutes on the equipment. The surface should remain wet (i.e. slightly damp) with 770 
the disinfectant to be considered effective though not wet enough to leave drops of liquid.  771 
In the event a manufacturer updates cleaning procedures for their device, the study team will 772 
adhere to the most current recommendations.  773 
There is the risk of blood sampling collection and contamination from sampling techniques. Hand 774 
washing with either soap & water or waterless hand sanitizer will be used prior to caring for the 775 
study subject. Gloves will be worn during blood sample collection and processing. Medical 776 
personnel will continue to practice hygiene for the subject’s protection (i.e. hand washing, 777 
changing gloves frequently, disposing needles properly). Gloves will be removed, and hands 778 
washed  or sanitized  prior to leaving and upon return to the subject’s room. Soiled linen will be 779 
changed to minimize the transfer of pathogenic organisms.  780 
 Hb1Ac Risk 781 
An NGSP Point of Care analyzer (i.e. DCA Vantage Analyzer) will be utilized at the research site to 782 
obtain the subject’s HbA1c level.  783 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 42 of 60 
  
 Other Risks  784 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 785 
the CGM, or to se cure the insulin infusion sets for the continuous subcutaneous insulin infusion.  786 
If these reactions occur, different adhesives or “under -taping” (such as with IV 3000, Tegaderm, 787 
etc.) will be tried, sites will be rotated frequently, and a mild topical steroid cream or other 788 
medication may be required.  789 
Whenever the skin is broken there is the possibility of an infection.  The CGM and pump infusion 790 
sites are inserted under the skin.  It is possible that any part that is inserted under the skin may 791 
cause an i nfection.  These occur very infrequently, but, if an infection was to occur, oral and/or 792 
topical antibiotics can be used.  The risk of skin problems could be greater if you use a sensor for 793 
longer than it is supposed to be used.  Therefore, participants wi ll be carefully instructed about 794 
proper use of the sensor.  795 
Data downloaded from the CGM, pump, glucometer, and ketone meter will be collected for the 796 
study as measures of diabetes self -management behaviors . Some people may  be uncomfortable 797 
with the researchers' having such detailed information about their daily diabetes habits.  798 
 Known Potential Benefits  799 
It is expected that this protocol will yield increased knowledge about using an automated closed- 800 
loop system with anticipatory action to control glucose levels . The individual participant may not 801 
benefit from study participation.  802 
 Risk Assessment  803 
Based on the facts that (1) adults with diabetes experience mild hypoglycemia and hyperglycemia 804 
frequently as a consequence of th e disease and its management, (2) the study intervention 805 
involves periodic automated insulin dosing that may increase the likelihood of hypoglycemia, and 806 
periodic automated attenuation of insulin delivery that may increase the likelihood of 807 
hyperglycemia, (3) mitigations are in place, and have been tested in prior studies using the 808 
investigational device system in the home setting, that limit the likelihood of excessive insulin 809 
dosing or prolonged withdrawal of insulin, and (4) rapid reversal of hypoglycemi a and 810 
hyperglycemia can be achieved .. In addition, it is the belief of the investigators that this study 811 
also presents prospect of direct benefit to the participants and general benefit to others with 812 
diabetes.  813 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 43 of 60 
  
 
 814 
The study is being conducted in compliance with the policies described in the study policies 815 
document, with the ethical principles that have their origin in the Declaration of Helsinki, with 816 
the protocol described herein, and with the standards of Good Clinical Practice (GCP).  817 
Whenever possible, data will be directly collected in electronic case report forms, which will be 818 
considered the source data.  819 
The protocol is considered a significant risk device study, due to the fact that the closed -loop 820 
system is experimental.  Therefor e, an investigational device exemption (IDE) from the U.S. Food 821 
and Drug Administration (FDA) is required to conduct the study.  822 
 
 823 
The study team will follow CDC guidelines that are in effect at the time of the study admission. 824 
Participants who do not provide a copy of their COVID -19 vaccination record will be considered 825 
not vaccinated.  826 
        Participants and Study Personnel  827 
We will follow a combination of approaches  to increase our likelihood of having all COV ID-free 828 
environment :    829 
• We will follow CDC and local guidelines in effect at the time of the study . 830 
• All participants will be ineligible if they have had known COVID -19 exposure or symptoms 831 
within 14 days of hotel admission .  832 
• Non -vaccinated  participants and study  staff (research coordinators, technicians, nurses , 833 
and physicians ) will be tested with a n FDA authorized COVID -19 test  approximately 72 834 
hours before their participation in the study hotel.  Those with positive tests will be 835 
excluded from the study.   836 
• Any participants with positive test will be discharged from the study.  Hotel rooms of 837 
these participants will be restricted from future use. We will limit  any personal 838 
interaction between study personnel and these individuals.  We will f ollow local 839 
guidelines in effect at the time of study to guide  interactions.  840 
•   All study staff onsite will abide by UVa clinical protocols currently in place at the time of 841 
the study  for healthcare workers which stands as the standard- of care for those involved 842 
in patient care.  This  protocol  may  include use of the HOOS Health Check app.     843 
  Environment  844 
The study  team will adhere to current hotel guidelines.   845 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 44 of 60 
  Chapter 11    Adverse Events, Devic e Issues, and Stopping Rules  846 
 
 847 
 Adverse Events (AE)  848 
Any untoward medical occurrence in a study participant, irrespective of the relationship between 849 
the adverse event and the device(s) under investigation ( section 11.2) for reportable adverse 850 
events for this protocol).  851 
Positive pregnancy test will be not considered adver se event .  852 
 Serious  Adverse Event (SAE)  853 
 Any untoward medical occurrence that:  854 
• Results in death.  855 
• Is life -threatening; (a non- life-threatening event which, had it been more severe, might 856 
have become life- threatening, is not necessarily considered a serious adverse event).  857 
• Requires inpatient hospi talization or prolongation of existing hospitalization.  858 
• Results in persistent or significant disability/incapacity or substantial disruption of the 859 
ability to conduct normal life functions ( life threatening).  860 
• Is a congenital anomaly or birth defect.  861 
• Is con sidered a significant medical event by the investigator based on medical judgment 862 
(e.g., may jeopardize the participant or may require medical/surgical intervention to 863 
prevent one of the outcomes listed above).  864 
 Unanticipated Adverse Device Effect (UADE)  865 
Any serious adverse effect on health or safety or any life- threatening problem or death caused 866 
by, or associated with, a device, if that effect, problem, or death was not previously identified in 867 
nature, severity, or degree of incidence in the investigationa l plan or application (including a 868 
supplementary plan or application), or any other unanticipated serious problem associated with 869 
a device that relates to the rights, safety, or welfare of participants (21 CFR 812.3(s)).  870 
 Adverse Device Effect (ADE)  871 
Any untoward medical occurrence in a study participant which the device may have caused or to 872 
which the device may have contributed . 873 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 45 of 60 
  
 Device Complaints and Malfunctions  874 
A device complication or complaint is something that happens to a device or related to device 875 
performance, whereas an adverse event happens to a participant . A device complaint may occur 876 
independently from an AE, or along with an AE . An AE may occur without a device complaint or 877 
there may be an AE related to a device complaint.  A device malfunction  is any failure of a device 878 
to meet its performance specifications or otherwise perform as intended.  Performance 879 
specifications include all claims made in the labelling  for the device.  The intended performance 880 
of a device refers to the intended use for which the device is labelled  or marketed. (21 CFR 803.3).   881 
 
 882 
For this protocol, a reportable adverse event includes any untoward medical occurrence that 883 
meets one of the following criteria:  884 
• A serious adverse event  as defined in section 11.2  885 
• An Adverse Device Effect as defined in section 11.1.4, unless excluded from reporting in 886 
section 11.7  887 
• An Adverse Event as defined in section 11.1.1 occurring in association with a study 888 
procedure  889 
• An AE as defined in section 11.1.1 which leads to discontinuation of a study device for 2 890 
or more hours  891 
• Hypoglycemia meeting the definition of severe hypoglycemia as defined in section 11.2.1  892 
• Diabetic ketoacidosis (DKA) as defined in section 11.2.2 or in the absence of  DKA, a 893 
hyperglycemic or ketosis event meeting the criteria defined below  894 
Hypoglycemia and hyperglycemia not meeting the criteria below will not be recorded as adverse 895 
events unless associated with an Adverse Device Effect . Skin reactions from sensor placement 896 
are only reportable if severe and/or required treatment.  897 
 Hypoglycemia Event  898 
Hypoglycemia not associated with an Adverse Device Effect is only reportable as an adverse event 899 
when the following definition for severe hypoglycemia is met:   900 
• the event required assistance of another person due to altered consciousness, and 901 
required another person to actively administer carbohydrate, glucagon, or other 902 
resuscitative actions  903 
• impaired cognitively to the point that he/she was unable to treat himself/herself, was 904 
unable to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or 905 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 46 of 60 
  experienced seizure or coma . These episodes may be associated with sufficient 906 
neurog lycope nia to induce seizure or coma  907 
• if plasma glucose measurements are not available during such an event, neurological 908 
recovery attributable to the restoration of plasma glucose to normal is considered 909 
sufficient evidence that the event was induced by a l ow plasma glucose concentration  910 
 Hyperglycemia Events/Diabetes Ketoacidosis  911 
Hyperglycemia not associated with an Adverse Device Effect is only reportable as an adverse 912 
event when one of the following four  criteria is met:  913 
• the event involved DKA, as defined by the Diabetes Control and Complications Trial 914 
(DCCT) and described below  evaluation or treatment was obtained at a health care 915 
provider facility for an acute event involving hyperglycemia or ketosis  916 
• blood ketone level ≥1.5 mmol/L and communication occurred with a health care provider 917 
at the time of the event  918 
• blood ketone level  ≥3.0 mmol/L, even if there was no communication with a health care 919 
provider  920 
Hyperglycemic events are classified as DKA if the following are present:  921 
• Symptoms such as polyuria, polydipsia, nausea, or vomiting  922 
• Serum ketones ≥1.5 mmol/L or large/moderate uri ne ketones  923 
• Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15  924 
• Treatment provided in a health care facility  925 
All reportable Adverse Events —whether volunteered by the participant, discovered by study 926 
personnel during questioning, or detected through physical examination, laboratory test, or 927 
other means —will be reported on an adverse event form online.  Each adverse event form is 928 
reviewed by the study PI to verify the coding and the reporting that is required.  929 
 
 930 
The study investigator will assess the relationship of any adverse event to be related or unrelated 931 
by determining if there is a reasonable possibility that the adverse event may have been caused 932 
by the study device.  933 
To ensure consisten cy of adverse event causality assessments, investigators should apply the 934 
following general guideline when determining whether an adverse event is related:  935 
• There is a plausible temporal relationship between the onset of the adverse event and 936 
the study intervention, and the adverse event cannot be readily explained by the 937 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 47 of 60 
  participant’s clinical state, intercurrent illness, or concomitant therapies; and/or the 938 
adverse event follows a known pattern of response to the study intervention; and/or the 939 
adverse even t abates or resolves upon discontinuation of the study intervention or dose 940 
reduction and, if applicable, reappears upon re -challenge.  941 
• Evidence exists that the adverse event has an etiology other tha n the study intervention 942 
(e.g., pre-existing medical cond ition, underlying disease, intercurrent illness, or 943 
concomitant medication); and/or the adverse event has no plausible temporal 944 
relationship to study intervention. 945 
 
 946 
While we are taking significant steps to prevent transmission of COVID -19 during this study, there 947 
is a possibility that participants, based either on exposure before the hotel admission or during 948 
the stay, are infected with COVID -19.  Infection with COVID -19 could be determined by testing 949 
48-hours prior to study admission and the day of admission for participants (in which case would 950 
be deemed not related to the study ) or onset of new symptoms during the stay. Any appearance 951 
of COVID -19 symptoms in participants will be cause for repeat COVID -19 testing an d quarantine  952 
until test results are returned.  If this  COVID  -19 test is positive, the participant  will be discharged 953 
from the study . Study team follow applicable local guidelines in effect at the time of study.   954 
In the event of a COVID -19 positive test in a participant , the study team will follow up with the 955 
participant via phone until conclusion of treatment  for the COVID -19 related sy mptoms . All 956 
participants will be asked to follow up via phone with the study team in the event of a positive 957 
test within 1 4 days after discharge from the hotel.  958 
 
 959 
The intensity of an adverse event will be rated on a three -point scale: (1) mild, (2) moderate, or 960 
(3) severe . It is emphasized that the term severe is a measure of intensity: thus, a severe adverse 961 
event is not necessarily serious . For example, itching for several days may be rated as severe, but 962 
may not be clinically serious.  963 
• MILD: Usually transient, requires no special treatment, and does not interfere with the 964 
participant’s daily activit ies. 965 
• MODERATE: Usually causes a low level of inconvenience or concern to the participant 966 
and may interfere with daily activities but is usually ameliorated by simple therapeutic 967 
measures.  968 
• SEVERE: Interrupts a participant’s usual daily activities and generally requires systemic 969 
drug therapy or other treatment.  970 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 48 of 60 
  
 
 971 
Adverse events will be coded by the Study PI per the UVA IRB website instructions (i.e. mild, 972 
moderate, severe).   The study PI will review the investigator assessment of causality and may 973 
agree or disagree.  The study PI  assessments will be recorded.  The study PI will have the final say 974 
in determining the causality.  975 
Adverse events that continue after the participant’s discontinuation or completion of the study 976 
will be followed until their medical outcome is determined or until no further change in the 977 
condition is expected.  978 
 
 979 
The outcome of each reportable adverse event will be classified by the investigator as follows:  980 
• RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae.  981 
Record the AE/SAE stop date.  982 
• RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized 983 
without change in the event anticipated.  Reco rd the AE/SAE stop date.  984 
• FATAL – A fatal outcome is defined as the SAE that resulted in death. Only the event that 985 
was the cause of death should be reported as fatal.  AEs/SAEs that were ongoing at the 986 
time of death; however, were not the cause of death, w ill be recorded as “resolved” at 987 
the time of death.  988 
• NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as the 989 
event was ongoing with an undetermined outcome.  990 
• An ongoing outcome will require follow -up by the site in order to determine the f inal 991 
outcome of the AE/SAE.  992 
• The outcome of an ongoing event at the time of death that was not the cause of death, 993 
will be updated and recorded as “resolved” with the date of death recorded as the stop 994 
date.  995 
• UNKNOWN – An unknown outcome is defined as an ina bility to access the participant or 996 
the participant’s records to determine the outcome (for example, a participant that was 997 
lost to follow -up). 998 
All clinically significant abnormalities of clinical laboratory measurements or adverse events 999 
occurring during the study and continuing at study termination should be followed by the 1000 
participant’s physician and evaluated with additional tests (if necessary) until diagnosis of the 1001 
underlying cause, or resolution. Follow -up information should be recorded on source do cuments.  1002 
If any reported adverse events are present when a participant completes the study, or if a 1003 
participant is withdrawn from the study due to an adverse event, the participant will be 1004 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 49 of 60 
  contacted for re -evaluation within 2 weeks.  If the adverse event h as not resolved, additional 1005 
follow -up will be performed as appropriate.  Every effort should be made by the Investigator or 1006 
delegate to contact the participant until the adverse event has resolved or stabilized.  1007 
 
 1008 
All UADEs, ADEs, de vice complaints, and device malfunctions will be reported irrespective of 1009 
whether an adverse event occurred, except in the following circumstances.  1010 
The following device issues are anticipated and will not be reported but will reported as an 1011 
Adverse Event i f the criteria for AE reporting described above are met:  1012 
• Component disconnections  1013 
• CGM sensors lasting fewer than the number of days expected per CGM labelling  1014 
• CGM tape adherence issues  1015 
• Pump infusion set occlusion not leading to ketosis  1016 
• Battery lifespan def iciency due to inadequate charging or extensive wireless 1017 
communication  1018 
• Intermittent device component disconnections/communication failures not leading to 1019 
system replacement  1020 
• Device issues clearly addressed in the user guide manual that do not require additi onal 1021 
troubleshooting  1022 
• Skin reactions from CGM sensor placement or pump infusion set placement that do not 1023 
meet criteria for AE reporting  1024 
 
 1025 
• UADEs must be reported within 10 working days to the FDA  after the sponsor first 1026 
receives noti ce of the adverse effect.  1027 
• Other reportable adverse events, device malfunctions (with or without an adverse event) 1028 
and device complaints should be reported promptly, but there is no formal required 1029 
reporting period.  1030 
• The IDE Sponsor will investigate the UADE  and if indicated, report the results of the 1031 
investigation to the IRBs  FDA and DSMB  within 10 working days of the study team  1032 
becoming aware of the UADE per 21CFR 812.46(b) (2).  1033 
• The FDA and DSMB  will determine if the UADE presents an unreasonable risk to 1034 
participants. If so, the Study PI must ensure that all investigations, or parts of 1035 
investigations presenting that risk, are terminated as soon as possible but no later than 5 1036 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 50 of 60 
  working days makes this determination and no later than 15 working  days after firs t 1037 
receipt notice of the UADE.  1038 
• In the case of a device system component malfunction (e.g. pump, CGM, control 1039 
algorithm), information will be forwarded to the responsible manufacturer by the study 1040 
personnel . 1041 
 
 1042 
 Participant Discontinuation  1043 
Rules for discontinuing study device use are described below.  1044 
• The investigator believes it is unsafe for the participant to continue on the intervention.  1045 
This could be due to the development of a new medical condition or worsening of an 1046 
existing condition; or participant behavior contrary to the indications for use of the 1047 
device that imposes on the participant’s safety  1048 
• The participant requests that the treatment be stopped  1049 
• The participant tests positive for COVID -19 (during study testing o r otherwise within 14 1050 
days of study start) or subsequently develops symptoms for COVID -19 and tests positive.  1051 
• Two distinct episodes of DKA , or one distinct  episode of DKA attributable to study device 1052 
use. 1053 
• Two distinct severe hypoglycemia events meeting the definition  in section 11.2.1 of the 1054 
protocol, or one distinct severe hypoglycemia event attributa ble to study device use  and 1055 
meeting the definition in section 11.2.1 of the protocol.  1056 
 Suspending/Stopping Overall Study  1057 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or severe 1058 
hyperglycemia event (as defined in secti on 11.2.2 ), use of the study device system will be 1059 
suspended while the problem is diagnosed.  1060 
In the even t that two distinct episodes of DKA  or two distinct severe hyp oglycemia events as 1061 
defined in section 11.2 occur , the overall study would be suspended while the underlying 1062 
conditions are determined.   1063 
In addition,  study activities could be similarly suspended if the manufacturer of any constituent 1064 
study device requires stoppage of device use for safety reasons (e.g. product recall).  The affected 1065 
study activities may resume if the underlying problem can be correcte d by a protocol or system 1066 
modification that will not invalidate the results obtained prior to suspension. The Study PI will 1067 
review all adverse events and adverse device events that are reported during the study.  The 1068 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 51 of 60 
  Study PI may request suspension of study activities or stoppage of the study is deemed necessary 1069 
based on the totality of safety data available.  1070 
 
 1071 
A Data and Safety Monitoring Board (DSMB) will review compiled safety data at per iodic intervals. In 1072 
addition, the DSMB will review all DKA and severe hypoglycemia irrespective of relatedness to study 1073 
device use, and all serious events (including UADEs) related to study device use at the time of 1074 
occurrence. The DSMB can request modifications to the study protocol or suspension or outright 1075 
stoppage of the study if deemed necessary based on the totality of safety data available. Details 1076 
regarding DSMB review will be documented in a separate DSMB document.  1077 
 
 1078 
A da ta breach is defined in the HITECH Act (43 USC 17932) as an unauthorized acquisition, access, 1079 
or use of protected health information (PHI) that compromises the security or privacy of such 1080 
information.   1081 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 52 of 60 
  Chapter 12  Miscellaneous Considerations  1082 
 
 1083 
Participants using glulisine at the time of enrollment will be asked to contact their personal 1084 
physician to change their prescribed personal insulin to lispro or aspart  for the duration of the 1085 
trial.  1086 
The study devices (study ins ulin pump, study CGM) must be removed before Magnetic Resonance 1087 
Imaging (MRI), Computed Tomography (CT) or diathermy treatment. Participants may continue 1088 
in the trial after temporarily discontinuing use if requiring one of the treatments above.  1089 
 
 1090 
Participation in the study is voluntary. Participant may withdraw at any time.  For  participants 1091 
who do withdraw  from the study, the study team will determine if their data will be used in 1092 
analysis.  1093 
 
 1094 
For security and confidentiality purposes, subjects will be assigned an identifier that will be used 1095 
instead of their name.  Protected health information gathered for this study may be shared with 1096 
the third -party collaborators.  De -identified subject information may also be provided to 1097 
collaborators involved in the study after the appropriate research agreement has been executed.   1098 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 53 of 60 
  Chapter 13  Statistical Consideration  1099 
 
 1100 
We will conduct a paired comparison of outcomes between each admission (FCL vs. FCL+, HCL vs 1101 
FCL, and FCL+ vs HCL), using Student paired t -test for percent in ranges and average CGM, and 1102 
Wilcoxon test  for overtly non normally distributed residuals (which often occur with outcomes 1103 
such as % time below 70mg/dL, as well as 50, or 60mg/dL, and % time abov e 250mg/dL). 1104 
Furthermore, we will use repeated  measure ANOVA 3x2 with within factors and contrasts (to 1105 
differentiate the repeated measures) if  covariates are deemed necessary in the analysis.  1106 
We do not plan to correct for multiple comparisons.  1107 
We do not expect substantial missing values in this highly supervised study, but if more than 3 1108 
subjects  have one or more missing admissions , we will consider switching from RANOVA to mixed 1109 
model  repeated  measures.  1110 
 
 1111 
The hypotheses for the primary outcome are:  1112 
a. Null Hypothesis: There is no difference in the time spent in the 70 -180mg/dL range within the 1113 
breakfast postprandial period (mealtime to mealtime+5h) between FCL and FCL+ (without and 1114 
with anticipation respectively)  1115 
b. Alternative Hypoth esis: There is a difference in the time spent in the 70 -180mg/dL range within 1116 
the breakfast postprandial period (mealtime to mealtime+5h) a between FCL and FCL+ (without 1117 
and with  anticipation respectively) . 1118 
 
 1119 
The main  study is itself  a pilot study to assess glycemic responses to three different approaches 1120 
to insulin dosing for carbohydrate ingestion , with different approaches to the Rocket AP system 1121 
(1) without the meal anticipation module and without carbohydrate announcement (FCL), 2) with 1122 
the meal anticipation module on and without carbohydrate announcement (FCL+), or 3) with the 1123 
meal anticipation module on and with carbohydrate announcement (HCL) , in random order).   1124 
This information is detailed in Table 1.  1125 
Randomization will occur via selection from the above list using permuted blocks in groups of 6.   1126 
 
 1127 
As a Preliminary  Study, the goal will be to complete up to 36 participants in the main study to 1128 
provide data from a variety of individuals. This number was chosen out of feasibility and not from 1129 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 54 of 60 
  a formal power calculation , and revised when new data (see reference  5) indicated that the 1130 
outcome variance was likely to be greater than originally assumed . The pilot study for this 1131 
proposal will assess ease of system use in up to 3 individuals prior to the beginning of  the main 1132 
study. Based on this empirical sample size, we would detect an effect size of approximately 0.5 1133 
at 80% power , and 0.6 at 95% power . Based on the recommended MCID of 5% TIR  over a day, 1134 
and assuming no influence of meal on overnight (midnight -6AM)  control  at TIR=90%, this would 1135 
lead to an improvement in TIR of approximately  11% during the breakfast regimen . Considering 1136 
the broad variability observed during un -bolused prandial control  (SD TIR≈22% from Garcia- Tirado 1137 
et al 2021, reference  5), this leads to a MC ID-derived Cohen -d effect size of approximately 0.5  1138 
 
 1139 
 Primary Efficacy Endpoint  1140 
The study design allows for multiple comparis ons of blood glucose control during the study meals 1141 
and treatment sessions, with for the primary comparison of interest being between the RocketAP 1142 
with and without the meal anticipation module, without announcement of carbohydrate. Our 1143 
primary endpoint is CGM time -in-range 70- 180 mg/dL for the period between breakfast and 1144 
lunch (approximately 5h). Additional comparisons are made between the RocketAP system 1145 
without vs. with normal carbohydrate announcement (which determines efficacy vs. premeal 1146 
bolus).  1147 
 Secon dary Outcomes 1148 
Each admission is separated in 5 windows of analysis:  1149 
1. The entirety of the admission (24h: 4pm to 4pm)  1150 
2. The 2 hours between expected dinner time and actual dinner time (day 1).  1151 
3. The overnight period (midnight to 6am day 2)  1152 
4. The window between the expected breakfast time and noon on day 2, ~5h (primary 1153 
outcome)  1154 
5. The 4h following lunch (noon- 4pm day 2)  1155 
For each of these periods we will compute the following outcomes:  1156 
5. Number of hypoglycemia events defined as at least two consecutive CGM values 1157 
<70mg/dL or a hypoglycemia treatment (two events separated by less than 30 minutes 1158 
are counted as one).  1159 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 55 of 60 
  6. Percent CGM time < 70 mg/dL  1160 
7. Percent CGM time between 80 -140mg/dL  1161 
8. Percent CGM time between 70 -180mg/dL  1162 
9. Percent CGM time > 180 mg/dL  1163 
10. Percent CGM time > 250 mg/dL  1164 
11. Units of insulin injected  1165 
12. Area under the curve when accounting for starting BG  1166 
13. Low Blood Glucose Index  1167 
14. High Blood Glucose Index  1168 
15. CGM coefficient of variation  1169 
 
 1170 
We will assess for the system’s functionality, inclu ding the ability of the system to run its code 1171 
without error (delivering insulin safely, as planned), as well as its ability to avoid low BG <70 1172 
mg/dL.  1173 
 
 1174 
Baseline demographic and clinical characteristics of the cohort of all r andomized participants will 1175 
be summarized in a table using summary statistics appropriate to the distribution of each 1176 
variable. Descriptive statistics will be displayed overall and by treatment group.  1177 
Will include:  1178 
1. Age 1179 
2. HbA1c  1180 
3. Gender  1181 
4. Race/ethnicity  1182 
5. CGM use b efore enrollment  1183 
6. AID use before enrollment  1184 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 56 of 60 
  7. Diabetes duration  1185 
8. BMI 1186 
9. Total Daily Insulin  1187 
 
 1188 
The following tabulations and analyses will be performed during time on the UVa AP systems  to 1189 
assess device issues:  1190 
1. Device malfunctions requiring study team contact and other reported device issues  1191 
2. % time CGM data available  1192 
3. % time with closed loop control   1193 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 57 of 60 
  Chapter 14   Data Collection and Monitoring 1194 
 
 1195 
The study data are collected through a combination of case report forms (electronic and paper) 1196 
and electronic device data files obtained from the software and individual hardware 1197 
components . These electronic device files and electronic CRFs are considered the primary source 1198 
documentation.  1199 
When data are directly collected in electronic case report forms, this will be considered the 1200 
source data.  Records will be maintained in accordance with ICH E6 and institutional regulatory 1201 
requirements for the protection of confidentiality of participants. 1202 
 
 1203 
Study docume nts should be retained for a minimum of 2 years after the last approval of a 1204 
marketing application in an ICH region and until there are no pending or contemplated marketing 1205 
applications in an ICH region or until at least 2 years have elapsed since the form al 1206 
discontinuation of clinical development of the investigational product.  These documents should 1207 
be retained for a longer period, however, if required by local regulations . No records will be 1208 
destroyed without the written consent of the sponsor, if appli cable . It is the responsibility of the 1209 
sponsor to inform the investigator when these documents no longer need to be retained.  1210 
 
 1211 
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Prac tices 1212 
(GCP), or procedure requirements.  The noncompliance may be either on the part of the 1213 
participant, the investigator, or the study site staff . As a result of deviations, corrective actions 1214 
may be developed by the site and implemented as appropriate.  Major deviations will be reported 1215 
to the IRB -HSR within 7 calendar days of when the study team becomes aware of the event.  1216 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 58 of 60 
  Chapter 15   Ethics/Protection of Human Participants  1217 
 
 1218 
The investigator will ensure that this study is conducted in full conformi ty with Regulations for 1219 
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 1220 
CFR Part 56, and/or the ICH E6.  1221 
 
 1222 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 1223 
be submitted to the IRB for review and approval.  Approval of both the protocol and the consent 1224 
form must be obtained before any participant is enrolled.  Any amendment to the protocol will 1225 
require review and approval by the IRB before the changes are implemented to the study.  All 1226 
changes to the consent form will be IRB approved; a determination will be made regarding 1227 
whether previously consented participants need to be re -consented.  1228 
 
 1229 
 Consent Procedures and Documentation 1230 
Informed consent is a process that is initiated prior to an individual’s agreement to participate in 1231 
the study and continues throughout the individual’s study participation.  Extensive discussion of 1232 
risks and possible benefits of participation will be provided.  Consent forms will be IRB approved 1233 
and the participant will be asked to read and review the document.  The investigator or their 1234 
delegate will explain the research study to the participant  and answer any questions that m ay 1235 
arise.  All participants will receive a verbal explanation in terms suited to their comprehension of 1236 
the purposes, procedures, and potential risks of the study and of their rights as research 1237 
participants.  P articipant  will have the opportunity to carefully review the written consent form 1238 
and ask questions prior to signing.  1239 
The participant and the parent(s)/ legal guardians will sign the informed consent document prior 1240 
to any procedures being done specifically for the study. The consent forms may be signe d 1241 
electronically with the use of the HIPAA compliant version of DocuSign. A copy of the informed 1242 
consent document will be given to the participant for their records.  The rights and welfare of the 1243 
participants will be protected by emphasizing to them that the quality of their medical care will 1244 
not be adversely affected if they decline to participate in this study.  1245 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 59 of 60 
  
 Participant and Data Confidentiality  1246 
The study monitor, representatives of the IRB or device company supplying study product may 1247 
inspect all docu ments and records required to be maintained by the investigator, including but 1248 
not limited to, medical records (office, clinic, or hospital) for the participants in this study.   1249 
The study participant’s contact information will be securely stored at the cl inical site for internal 1250 
use during the study.  At the end of the study, all records will continue to be kept in a secure 1251 
location for as long a period as dictated by local IRB and Institutional regulations.  1252 
Study participant research data, which is for purposes of statistical analysis and scientific 1253 
reporting, will be transmitted to and stored at the University of Virginia Center for Diabetes 1254 
Technology.  The study data entry and study management systems used by research staff will be 1255 
secured and passwor d protected.  At the end of the study, all study databases may be de- 1256 
identified and archived at the University of Virginia Center for Diabetes Technology.  1257 
CLINICAL PROTOCOL  
 
DCLP6 – Meal Anticipation  18-Nov-2021 Page 60 of 60 
  Chapter 16  References  1258 
1. B urdick J, Chase HP, Slover RH, et al. Missed insulin meal boluses an d elevated 1259 
hemoglobin A(1c) levels in children receiving insulin pump therapy. Pediatrics . Mar 1260 
2004;113(3):E221 -E224. doi:10. 1542/peds.113.3.e221  1261 
2. Cherñavvsky DR, DeBoer MD, Keith -Hynes P, et al. Use of an artificial pancreas among 1262 
adolescents for a missed  snack bolus and an underestimated meal bolus. Pediatr 1263 
Diabetes . Feb 2016;17(1):28- 35. doi:10.1111/pedi.12230  1264 
3. Garcia- Tirado J, Brown SA, Laichuthai N, et al. Anticipation of Historical Exercise Patterns 1265 
by a Novel Artificial Pancreas System Reduces Hypogl ycemia During and After Moderate - 1266 
Intensity Physical Activity in People with Type 1 Diabetes. Diabetes Technol Ther . Dec 1267 
2020;doi:10.1089/dia.2020.0516  1268 
4. Voysey, Merryn and Costa Clemens, Sue Ann and Madhi, Shabir A. et al and Group, Oxford 1269 
COVID Vaccine Tri al, Single Dose Administration, And The Influence Of The Timing Of The 1270 
Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV -19 (AZD1222) Vaccine. 1271 
Available at SSRN: https://ssrn.com/abstract=37772 68 1272 
5.Garcia- Tirado J, Diaz JL, Esquivel- Zuniga R, Koravi CL, Corbett JP, Dawson M, Wakeman C, 1273 
Barnett CL, Oliveri MC, Myers H, Krauthause K. Advanced Closed -Loop Control System 1274 
Improves Postprandial Glycemic Control Compared With a Hybrid Closed -Loop Syst em 1275 
Following Unannounced Meal. Diabetes Care. 2021 Oct 1;44(10):2379 -87. 1276 